BR9811458A - "sistema solvente para penetração melhorada de compostos farmacêuticos" - Google Patents

"sistema solvente para penetração melhorada de compostos farmacêuticos"

Info

Publication number
BR9811458A
BR9811458A BR9811458-1A BR9811458A BR9811458A BR 9811458 A BR9811458 A BR 9811458A BR 9811458 A BR9811458 A BR 9811458A BR 9811458 A BR9811458 A BR 9811458A
Authority
BR
Brazil
Prior art keywords
solvent system
pharmaceutical compounds
improved penetration
penetration
compound
Prior art date
Application number
BR9811458-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Rao Chakradhara
Jue-Chen Liu
Jonas C T Wang
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of BR9811458A publication Critical patent/BR9811458A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9811458-1A 1997-03-31 1998-03-03 "sistema solvente para penetração melhorada de compostos farmacêuticos" BR9811458A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82909197A 1997-03-31 1997-03-31
PCT/US1998/004033 WO1998043673A1 (en) 1997-03-31 1998-03-03 Solvent system for enhanced penetration of pharmaceutical compounds

Publications (1)

Publication Number Publication Date
BR9811458A true BR9811458A (pt) 2000-09-19

Family

ID=25253504

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811458-1A BR9811458A (pt) 1997-03-31 1998-03-03 "sistema solvente para penetração melhorada de compostos farmacêuticos"

Country Status (14)

Country Link
EP (1) EP0971746A1 (es)
JP (1) JP2001518879A (es)
KR (1) KR19980081207A (es)
CN (1) CN1252003A (es)
AR (1) AR012217A1 (es)
AU (1) AU6677698A (es)
BR (1) BR9811458A (es)
CA (1) CA2285368A1 (es)
CO (1) CO5050328A1 (es)
HU (1) HUP0001739A3 (es)
IL (1) IL132096A0 (es)
PL (1) PL335934A1 (es)
WO (1) WO1998043673A1 (es)
ZA (1) ZA982662B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
WO2000072818A1 (en) * 1999-05-27 2000-12-07 The Procter & Gamble Company Topical compositions providing improved treatment of skin or scalp fungal infections
GB0103046D0 (en) 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP5435836B2 (ja) * 2003-07-03 2014-03-05 大正製薬株式会社 外用抗真菌剤組成物
JP4784051B2 (ja) * 2003-07-03 2011-09-28 大正製薬株式会社 容器への吸着を防止した外用抗真菌組成物
DE102005059742A1 (de) 2005-12-13 2007-06-14 Beiersdorf Ag Transparentes Sonnenschutzmittel
US20080032994A1 (en) 2006-08-03 2008-02-07 Marcel Borgers Modified azole compounds as antifungal and antibacterial agents
WO2009013331A1 (en) * 2007-07-25 2009-01-29 Ixodes Gmbh Topical antibiotic composition for the prevention of lyme disease
WO2009028495A1 (ja) * 2007-08-27 2009-03-05 Nihon Nohyaku Co., Ltd. 真菌性皮膚炎用剤
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US9839611B2 (en) * 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
MY179756A (en) 2013-10-03 2020-11-12 Dow Pharmaceutical Sciences Stabilized efinaconazole formulations
CN105848719A (zh) 2013-11-22 2016-08-10 道尔医药科学公司 抗感染的方法、组合物和装置
CN115745757B (zh) * 2022-11-07 2024-04-26 中国人民解放军军事科学院军事医学研究院 一种液态多甘醇柱芳烃衍生物的合成及对经皮药效分子缓释的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2051998T3 (es) * 1988-02-29 1994-07-01 Pfizer Composiciones aumentadoras del flujo transdermal.
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
CN1106259A (zh) * 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂

Also Published As

Publication number Publication date
AR012217A1 (es) 2000-09-27
CO5050328A1 (es) 2001-06-27
EP0971746A1 (en) 2000-01-19
HUP0001739A3 (en) 2001-04-28
PL335934A1 (en) 2000-05-22
IL132096A0 (en) 2001-03-19
KR19980081207A (ko) 1998-11-25
AU6677698A (en) 1998-10-22
ZA982662B (en) 1999-09-30
HUP0001739A2 (hu) 2000-12-28
CN1252003A (zh) 2000-05-03
WO1998043673A1 (en) 1998-10-08
JP2001518879A (ja) 2001-10-16
CA2285368A1 (en) 1998-10-08

Similar Documents

Publication Publication Date Title
BR9811458A (pt) "sistema solvente para penetração melhorada de compostos farmacêuticos"
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
PT1087750E (pt) Formulacoes farmaceuticas para aerossois com duas ou mais substancias activas
IT1283102B1 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
FR2784294B1 (fr) Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
ES2162927T3 (es) Formulacion para la aplicacion por inhalacion.
BR9803300A (pt) Formulação farmacêutica.
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
BR9807234A (pt) Composição farmacêutica
BR0014818A (pt) Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
ES2149305T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0013009A (pt) Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos
BR9809508A (pt) Agente terapêutico para disfunção de ereção
BR9913135A (pt) Formulação oral
BR9908427A (pt) Composições farmacêuticas e uso das mesmas
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
DE59914183D1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
BR9812875A (pt) Processos para o tratamento de artrite reumatóide em um mamìfero, e para a fabricação de uma composição terapêutica para o tratamento de artrite reumatóide em um mamìfero, uso de um composto, e, composição farmacêutica
BR9707770C1 (pt) Tifluzamida com eficácia aperfeiçoada

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]